wikidoc - Changes related to "Category:Emergency medicine" [en]

Sandbox

2026-05-03T18:30:46Z

Show changes

Sandbox

2026-04-29T10:11:34Z

Replaced content with "== '''Thoracic Aortic Aneurysm Medical Therapy''' == <references />"

Show changes

Thoracic aortic aneurysm medical therapy

2026-04-29T10:10:34Z

Medical Therapy

Show changes

Sandbox

2026-04-28T01:40:03Z

Show changes

Supraventricular tachycardia

2026-04-27T17:08:57Z

Show changes

Chronic stable angina overview

2026-04-25T15:44:25Z

Treatment

Show changes

Sandbox

2026-04-23T00:19:19Z

Medical Treatment of Patients With Thoracic Aortic Disease

← Older revision		Revision as of 00:19, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 35:		Line 35:
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
	\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]		\|colspan="1" style="text-align:center; background:LightGreen"\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]
	\|-		\|-
	\|"'''1.''' Stringent control of ~~<nowiki>~~[[hypertension]]~~</nowiki>~~, ~~<nowiki>~~[[lipid profile]]~~</nowiki>~~ optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"		\|colspan="1" style="text-align:center; background:LightGreen"\|'''1.''' Stringent control of [[hypertension]], [[lipid profile]] optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"
	\|}		\|}

Sandbox

2026-04-22T17:31:17Z

Thoracic Aortic Aneurysm Medical Therapy ===== Overview ===Medical therapy for patients with a thoracic aortic aneurysm includes aggressive blood pressure control targeting a goal of 130/80 mmHg for all patients, heart rate reduction with beta-

Show changes

Heart failure resident survival guide

2026-04-21T11:24:22Z

Treatment of Heart Failure in Stage C and D

Show changes

Congestive heart failure Management of Acute heart failure

2026-04-18T10:39:34Z

Transitional care plan: components (Class 1 recommendation):[2]

Show changes

Sandbox

2026-04-16T00:52:30Z

← Older revision		Revision as of 00:52, 16 April 2026
Line 1:		Line 1:
			== ACS Treatment ==
			Primary Prevention:

	~~{{familytree/start}}~~		'''Equivalent intensity for CHD-risk equivalents (LoE: A):''' Patients with established CHD should be targeted for secondary prevention. Crucially, patients with a '''CHD risk equivalent''' — defined as atherosclerosis in other vascular beds, diabetes mellitus, chronic kidney disease, or a Framingham-calculated 10-year risk exceeding 20% — should receive '''the same intensity of risk factor intervention''' as those with overt, clinically apparent CHD.
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| A01 \| \| \| \| \| \|A01=Adult ALL }}~~
	~~{{familytree \| \|,\|-\|-\|-\|v\|-\|-\|-\|-\|-\|-\|+\|-\|-\|-\|-\|-\|-\|-\|-\|-\|.\| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| D01 \| \| D02 \| \| \| \| \| D03 \| \| \| \| \| \| \| \| D05 \| \| \| \|D01=Burkitt Leukemia\|D02=PH-Positive B-ALL\|D03=PH-negative B-ALL\|D05=T-ALL}}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	{{familytree \| E01 \| \| E02 \| \| E03 \| \| \| \| E04 \| \| E05 \| \| \| \| E06 \| \| \|E01=R-hyper CVAD<br> DA-R-EPOCH\|E02=Chemotherapt+TKI <br> Blinatumomab+TKI\|E03=Younger adults\|E04=Older Adults\|E05=ETP\|E06=Non ETP}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \|}}~~
	{{familytree \| \|!\| \| \| \|!\| \| \| F01 \| \| \| \| F02 \| \| F03 \| \| \| \| F04 \| \|F01=Chemotherapy+<br>blinatumomab\|F02=Chemotherapy+<br>blinatumumab+InO <br>Chemotherapy-free blinatumomab + InO\|F03=Chemotherapy+pegAsp+<br>nelarabine+venetoclax\|F04=Chemotherapy+pegAsp+<br>nelarabine}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|`\|-\|-\|-\|^\|-\|-\|-\|^\|-\|-\|v\|-\|-\|^\|-\|-\|-\|^\|-\|-\|-\|-\|-\|~~'~~\| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| G01 \| \| \| \| \| \| \| \| \| \| \| \| \| \|G01=<div style="float: left; text~~-~~align~~: ~~left; height~~: ~~3em; width: 20em;">~~ '''~~Measurable residual disease monitoring~~'''~~<br> </div>}} }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \| \| \| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| H01 \| \| \| \| \| \| \| \| \| \| \| \| \| \| \|H01=<div style="float: left; text~~-~~align: left;">~~'''~~Alloegenic hematopoietic stem cell transplant~~''' ~~<br>•Ph-like ALL~~ with ~~CRLF2 and JAK vairants<br>•High-risk cytogenetics in B-ALL<br>•High-risk Ph-positive B-ALL: IZKF1 genotype<br>•T-ALL: ETP-ALL<br>•Persistent measurable residual disease by NGS<br> </div>}}~~
	~~{{familytree/end}}~~

Low back pain conservative management

2026-04-14T16:24:46Z

Physical Therapy

← Older revision		Revision as of 16:24, 14 April 2026
(One intermediate revision by the same user not shown)
Line 14:		Line 14:
	According to a [[systematic review]] of [[randomized controlled trial]]s by the [[Cochrane Collaboration]], massage therapy, compared to inactive controls, over the short-term significantly reduced pain (SMD=0.75; large) and improved function (SMD=0.72; large).<ref name="pmid26329399">{{cite journal\| author=Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M\| title=Massage for low-back pain. \| journal=Cochrane Database Syst Rev \| year= 2015 \| volume= 9 \| issue= \| pages= CD001929 \| pmid=26329399 \| doi=10.1002/14651858.CD001929.pub3 \| pmc= \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26329399 }} </ref> However, the Cochrane concluded "very little confidence that massage is an effective treatment".		According to a [[systematic review]] of [[randomized controlled trial]]s by the [[Cochrane Collaboration]], massage therapy, compared to inactive controls, over the short-term significantly reduced pain (SMD=0.75; large) and improved function (SMD=0.72; large).<ref name="pmid26329399">{{cite journal\| author=Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M\| title=Massage for low-back pain. \| journal=Cochrane Database Syst Rev \| year= 2015 \| volume= 9 \| issue= \| pages= CD001929 \| pmid=26329399 \| doi=10.1002/14651858.CD001929.pub3 \| pmc= \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26329399 }} </ref> However, the Cochrane concluded "very little confidence that massage is an effective treatment".

	===~~Mckenzie Method~~===		=== Physical Therapy===
	The Mckenzie Method has been shown to be a modestly effective therapy for adults with chronic low back pain. A 2011 summary of 4 studies showed consistent significant improvement in pain and function although only one study had a large enough population to demonstrate effect sizes on pain and functional outcomes, 0.50 and 0.39 respectively.<ref name="pmid22135496">{{cite journal\| author=Dunsford A, Kumar S, Clarke S\| title=Integrating evidence into practice: use of McKenzie-based treatment for mechanical low back pain. \| journal=J Multidiscip Healthc \| year= 2011 \| volume= 4 \| issue= \| pages= 393-402 \| pmid=22135496 \| doi=10.2147/JMDH.S24733 \| pmc=PMC3215349 \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22135496 }} </ref>		The Mckenzie Method has been shown to be a modestly effective therapy for adults with chronic low back pain. A 2011 summary of 4 studies showed consistent significant improvement in pain and function although only one study had a large enough population to demonstrate effect sizes on pain and functional outcomes, 0.50 and 0.39 respectively.<ref name="pmid22135496">{{cite journal\| author=Dunsford A, Kumar S, Clarke S\| title=Integrating evidence into practice: use of McKenzie-based treatment for mechanical low back pain. \| journal=J Multidiscip Healthc \| year= 2011 \| volume= 4 \| issue= \| pages= 393-402 \| pmid=22135496 \| doi=10.2147/JMDH.S24733 \| pmc=PMC3215349 \| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22135496 }} </ref>

			A [[randomized controlled trial]] in 2015 found minimal benefit.<ref name="v851">{{cite journal \| last1=Fritz \| first1=Julie M. \| last2=Magel \| first2=John S. \| last3=McFadden \| first3=Molly \| last4=Asche \| first4=Carl \| last5=Thackeray \| first5=Anne \| last6=Meier \| first6=Whitney \| last7=Brennan \| first7=Gerard \| title=Early Physical Therapy vs Usual Care in Patients With Recent-Onset Low Back Pain: A Randomized Clinical Trial \| journal=JAMA \| volume=314 \| issue=14 \| date=2015-10-13 \| issn=0098-7484 \| doi=10.1001/jama.2015.11648 \| pmid = 26461996 \| page=1459 \| url=http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.11648 \| access-date=2026-04-12}}</ref> Outcomes were measured with the Oswestry Disability Index (ODI: range 0 to 100) which has a recommended minimum clinically important difference (MCID) of 6<ref name="pmid11175676">{{cite journal \| last1=Fritz \| first1=J. M. \| last2=Irrgang \| first2=J. J. \| title=A comparison of a modified Oswestry Low Back Pain Disability Questionnaire and the Quebec Back Pain Disability Scale \| journal=Physical Therapy \| volume=81 \| issue=2 \| date=2001 \| issn=0031-9023 \| pmid=11175676 \| doi=10.1093/ptj/81.2.776 \| pages=776–788 \| url=https://pubmed.gov/11175676 \| access-date=2026-04-14}}</ref>. While both the intervention and usual care group had improvement well above the MCID, the "Mean Difference Between Groups in Change from Baseline" were less than 4 at all time points.

	===Pilates===		===Pilates===

Back pain

2026-04-12T19:14:31Z

Treatment

← Older revision		Revision as of 19:14, 12 April 2026
Line 37:		Line 37:
	==Treatment==		==Treatment==

	[[Back pain medical therapy\|Medical Therapy]] \| [[Back pain surgery\|Surgery]] \| [[Back pain primary prevention\|Primary Prevention]] \| [[Back pain secondary prevention\|Secondary Prevention]] \| [[Back pain cost-effectiveness of therapy\|Cost-Effectiveness of Therapy]] \| [[Back pain future or investigational therapies\|Future or Investigational Therapies]] \| [[Back pain monitoring response to therapy\| Monitoring Response to Therapy]]		[[Back pain medical therapy\|Medical Therapy]] \| [[Low back pain conservative management]] \| [[Back pain surgery\|Surgery]] \| [[Back pain primary prevention\|Primary Prevention]] \| [[Back pain secondary prevention\|Secondary Prevention]] \| [[Back pain cost-effectiveness of therapy\|Cost-Effectiveness of Therapy]] \| [[Back pain future or investigational therapies\|Future or Investigational Therapies]] \| [[Back pain monitoring response to therapy\| Monitoring Response to Therapy]]

	==Lecture==		==Lecture==

Sudden cardiac death prognosis

2026-04-07T15:45:12Z

Prognosis of cardiac arrest in young athletes:

← Older revision		Revision as of 15:45, 7 April 2026
(One intermediate revision by the same user not shown)
Line 67:		Line 67:
	:* Women between 15-45 years old<ref name="pmid20228684">{{cite journal \|vauthors=Topjian AA, Localio AR, Berg RA, Alessandrini EA, Meaney PA, Pepe PE, Larkin GL, Peberdy MA, Becker LB, Nadkarni VM \|title=Women of child-bearing age have better inhospital cardiac arrest survival outcomes than do equal-aged men \|journal=Crit Care Med \|volume=38 \|issue=5 \|pages=1254–60 \|date=May 2010 \|pmid=20228684 \|pmc=3934212 \|doi=10.1097/CCM.0b013e3181d8ca43 \|url=}}</ref>		:* Women between 15-45 years old<ref name="pmid20228684">{{cite journal \|vauthors=Topjian AA, Localio AR, Berg RA, Alessandrini EA, Meaney PA, Pepe PE, Larkin GL, Peberdy MA, Becker LB, Nadkarni VM \|title=Women of child-bearing age have better inhospital cardiac arrest survival outcomes than do equal-aged men \|journal=Crit Care Med \|volume=38 \|issue=5 \|pages=1254–60 \|date=May 2010 \|pmid=20228684 \|pmc=3934212 \|doi=10.1097/CCM.0b013e3181d8ca43 \|url=}}</ref>
	:*Rapid intervention with a [[defibrillator]] increases [[survival rates]].<ref>{{cite journal \|author=Eisenberg MS, Mengert TJ \|title=Cardiac resuscitation \|journal=N. Engl. J. Med. \|volume=344 \|issue=17 \|pages=1304–13 \|year=2001 \|month=April \|pmid=11320390 \|doi= \|url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11320390&promo=ONFLNS19}}</ref><ref name="pmid12826637">{{cite journal \|author=Bunch TJ, White RD, Gersh BJ, ''et al'' \|title=Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation \|journal=N. Engl. J. Med. \|volume=348 \|issue=26 \|pages=2626–33 \|year=2003 \|month=June \|pmid=12826637 \|doi=10.1056/NEJMoa023053 \|url=}}</ref>		:*Rapid intervention with a [[defibrillator]] increases [[survival rates]].<ref>{{cite journal \|author=Eisenberg MS, Mengert TJ \|title=Cardiac resuscitation \|journal=N. Engl. J. Med. \|volume=344 \|issue=17 \|pages=1304–13 \|year=2001 \|month=April \|pmid=11320390 \|doi= \|url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11320390&promo=ONFLNS19}}</ref><ref name="pmid12826637">{{cite journal \|author=Bunch TJ, White RD, Gersh BJ, ''et al'' \|title=Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation \|journal=N. Engl. J. Med. \|volume=348 \|issue=26 \|pages=2626–33 \|year=2003 \|month=June \|pmid=12826637 \|doi=10.1056/NEJMoa023053 \|url=}}</ref>

			==== Prognosis of cardiac arrest in young athletes: ====

			* 58% survival rate was reported by the US Commotio Cordis Registry in 216 persons with sudden cardiac arrest due to commotio cordis (cardiac arrest due to VF triggered by blunt chest trauma) (age range, 0.2-51 years;mean,15years, 95% male) from 2006 through 2012.<ref name=":9">Maron BJ, Haas TS, Ahluwalia A, Garberich RF, Estes NA III, Link MS. Increasing survival rate from commotio cordis.HeartRhythm.2013;10(2):219-223. doi:10.1016/j.hrthm.2012.10.034</ref>
			* Prompt resuscitation and participation in organized competitive sports was associated with higher survival rates. Multivariate analysis identified participation in recreational sports with lower survival (odds ratio [OR] compared with organized competitive sports, 0.33; 95%CI,0.16-0.67) and onsite automated external defibrillator with higher survival (OR, 4.61; 95% CI, 1.43-14.88).<ref name=":9" />
			* Individuals aged 18 to 35 years with sports-related sudden cardiac arrest in Germany and France showed improved survival to hospital discharge with public automated external defibrillator use prior to EMS arrival (OR, 6.25; 95% CI, 1.48 43.20); individuals with sudden cardiac arrest who received both immediate bystander CPR and automated external defibrillator had 91%survival.<ref>Bohm P, Meyer T, Narayanan K, et al. Sports-related sudden cardiac arrest in young adults. Europace. 2023;25(2):627-633. doi:10.1093/ europace/euac172</ref>
			* A recent meta-analysis demonstrated that in sports related sudden cardiac arrest, bystander presence (OR, 2.55; 95%CI, 1.48-4.37), bystander CPR (OR, 3.84; 95% CI, 2.36-6.25), and bystander automated external defibrillator use (OR, 5.25; 95%CI,3.58-7.70) were associated with improved survival.<ref>Michelland L, Murad MH, Bougouin W, et al. Association between basic life support and survival in sports-related sudden cardiac arrest: a meta-analysis. Eur Heart J. 2023;44(3):180-192. doi:10.1093/eurheartj/ehac586</ref>

	==References==		==References==

Sudden cardiac death screening

2026-04-07T15:15:15Z

Screening in young athletes:

← Older revision		Revision as of 15:15, 7 April 2026
(One intermediate revision by the same user not shown)
Line 16:		Line 16:
	**LQTS Risk Calculator		**LQTS Risk Calculator
	**VA calculator		**VA calculator

			=== Screening in young athletes: ===
			The American Heart Association–American College of Cardiology consensus statement<ref name=":1">Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 2: preparticipation screening for cardiovascular disease in competitive athletes: a scientific statement from the American Heart Association and AmericanCollege of Cardiology. Circulation. 2015;132(22):e267-e272.</ref> on preparticipation screening recommends the American Heart Association 14-point screening guide, including a comprehensive history taking and a physical examination for young athletes (class I recommendation), but does not recommend routine ECG screening of young adults (athletes and non-athletes) in the general population (class III), due to concerns about diagnostic accuracy, cost-effectiveness, and availability of physicians and equipment needed for screening. ECG or transthoracic echocardiography should only be performed in select individuals in whom genetic,congenital,or other cardiovascular abnormalities are suspected or identified (class IIb).<ref name=":1" />

			However, recent ESC guideline recommends a 12-lead ECG as part of preparticipation for all competitive athletes younger than 35 years (class IIa).<ref name="pmid36017572" /> This recommendation was supported by outcome data from the Veneto region, which showed declining incidence of sudden death in young competitive athletes after introduction of a nationwide prescreening program using ECG.<ref>Corrado D, Basso C, Pavei A, Michieli P, Schiavon M,ThieneG. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA.2006;296(13):1593-1601. doi:10.1001/jama.296.13.1593</ref> Some data suggest that compared with history and physical examination, ECG may provide superior accuracy to identify potential risk of sudden death, primarily due to detection of preexcitation syndromes (sensitivity 88% vs 19%, specificity 98% vs 75%).<ref>Williams EA, Pelto HF, Toresdahl BG, et al. Performance of the American Heart Association (AHA)14-point evaluation versus electrocardiography for the cardiovascular screening of high school athletes: a prospective 996 study. J AmHeartAssoc.2019;8(14):e012235. doi:10.1161/JAHA.119.012235</ref>,<ref>Goff NK, Hutchinson A, Koek W, Kamat D. Meta-analysis on the effectiveness of ECG screening for conditions related to sudden cardiac death in young athletes. Clin Pediatr (Phila). 2023;62(10):1158-1168. doi:10.1177/ 00099228231152857</ref>

			In the last 2 decades, preparticipation screening for early identification of young competitive athletes at risk of sudden cardiac arrest in high school, college, and professional settings has been investigated. A comparable incidence of cardiovascular deaths was found between 1993 and 2015 in these studies screening competitive athletes. In the Veneto region of Italy, where ECG is routinely employed as part of preparticipation screening, and those in the US (Minnesota), where preparticipation prescreening is limited to history and physical examination.<ref>Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS. Comparison of U.S.and Italian experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies. Am J Cardiol. 2009;104(2):276-280. doi:10.1016/j.amjcard.2009. 03.037</ref>

Sudden cardiac death risk factors

2026-04-06T16:54:56Z

Risk Factors

@@ Line 20: / Line 20: @@
 :*[[Early repolarization]] patten in early phase of [[MI]]<ref name="NaruseTada2012">{{cite journal|last1=Naruse|first1=Yoshihisa|last2=Tada|first2=Hiroshi|last3=Harimura|first3=Yoshie|last4=Hayashi|first4=Mayu|last5=Noguchi|first5=Yuichi|last6=Sato|first6=Akira|last7=Yoshida|first7=Kentaro|last8=Sekiguchi|first8=Yukio|last9=Aonuma|first9=Kazutaka|title=Early Repolarization Is an Independent Predictor of Occurrences of Ventricular Fibrillation in the Very Early Phase of Acute Myocardial Infarction|journal=Circulation: Arrhythmia and Electrophysiology|volume=5|issue=3|year=2012|pages=506–513|issn=1941-3149|doi=10.1161/CIRCEP.111.966952}}</ref>
 :*Family history of premature death (sudden and unexpected) before age 50 attributed to [[heart]] disease in > 1 relative, presence of [[heart]] disease in close relative less than age 50, presence of ion [[channelopathies]] in family members
 ==References==

← Older revision		Revision as of 00:52, 16 April 2026
Line 1:		Line 1:
			== ACS Treatment ==
			Primary Prevention:

	~~{{familytree/start}}~~		'''Equivalent intensity for CHD-risk equivalents (LoE: A):''' Patients with established CHD should be targeted for secondary prevention. Crucially, patients with a '''CHD risk equivalent''' — defined as atherosclerosis in other vascular beds, diabetes mellitus, chronic kidney disease, or a Framingham-calculated 10-year risk exceeding 20% — should receive '''the same intensity of risk factor intervention''' as those with overt, clinically apparent CHD.
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| A01 \| \| \| \| \| \|A01=Adult ALL }}~~
	~~{{familytree \| \|,\|-\|-\|-\|v\|-\|-\|-\|-\|-\|-\|+\|-\|-\|-\|-\|-\|-\|-\|-\|-\|.\| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| D01 \| \| D02 \| \| \| \| \| D03 \| \| \| \| \| \| \| \| D05 \| \| \| \|D01=Burkitt Leukemia\|D02=PH-Positive B-ALL\|D03=PH-negative B-ALL\|D05=T-ALL}}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| \|,\|-\|-\|^\|-\|-\|.\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	{{familytree \| E01 \| \| E02 \| \| E03 \| \| \| \| E04 \| \| E05 \| \| \| \| E06 \| \| \|E01=R-hyper CVAD<br> DA-R-EPOCH\|E02=Chemotherapt+TKI <br> Blinatumomab+TKI\|E03=Younger adults\|E04=Older Adults\|E05=ETP\|E06=Non ETP}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \|}}~~
	{{familytree \| \|!\| \| \| \|!\| \| \| F01 \| \| \| \| F02 \| \| F03 \| \| \| \| F04 \| \|F01=Chemotherapy+<br>blinatumomab\|F02=Chemotherapy+<br>blinatumumab+InO <br>Chemotherapy-free blinatumomab + InO\|F03=Chemotherapy+pegAsp+<br>nelarabine+venetoclax\|F04=Chemotherapy+pegAsp+<br>nelarabine}}
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|!\| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| \|!\| \| \| \| \| \|!\| \| \| }}~~
	~~{{familytree \| \|`\|-\|-\|-\|^\|-\|-\|-\|^\|-\|-\|v\|-\|-\|^\|-\|-\|-\|^\|-\|-\|-\|-\|-\|~~'~~\| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| G01 \| \| \| \| \| \| \| \| \| \| \| \| \| \|G01=<div style="float: left; text~~-~~align~~: ~~left; height~~: ~~3em; width: 20em;">~~ '''~~Measurable residual disease monitoring~~'''~~<br> </div>}} }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| \|!\| \| \| \| \| \| \| \| \| \| \| \| \| \| }}~~
	~~{{familytree \| \| \| \| \| \| \| \| \| \| \| \| H01 \| \| \| \| \| \| \| \| \| \| \| \| \| \| \|H01=<div style="float: left; text~~-~~align: left;">~~'''~~Alloegenic hematopoietic stem cell transplant~~''' ~~<br>•Ph-like ALL~~ with ~~CRLF2 and JAK vairants<br>•High-risk cytogenetics in B-ALL<br>•High-risk Ph-positive B-ALL: IZKF1 genotype<br>•T-ALL: ETP-ALL<br>•Persistent measurable residual disease by NGS<br> </div>}}~~
	~~{{familytree/end}}~~